



BREAKTHROUGH PEPTIDE THERAPEUTICS

19 June 2017

PHYLOGICA ANNOUNCES APPOINTMENTS OF CEO AND CHIEF SCIENCE OFFICER, AND SECURES \$5 MILLION IN NEW FUNDING

Phylogica (ASX: PYC) is pleased to announce that it has secured \$5m in additional funding at \$0.04 a share (at market pricing) to enhance the pre-clinical validation of its world leading intra-cellular delivery technology and proprietary drug cargoes.

Access to these additional funds has allowed the company to appoint an international and high profile executive management team to oversee the pre-clinical development of the lead candidates originating from the Phylomer platform. Stephanie Unwin has been appointed as Phylogica's Chief Executive Officer and Dr Robert Hayes will commence immediately as our Chief Scientific Officer. These two appointments provide the company with both deep commercial capabilities and extensive drug development expertise at a critical time for Phylogica and reflect the increasing promise and maturity of the company's transformational drug delivery technology.

Stephanie Unwin brings extensive senior executive and commercial experience to PYC. Since becoming an executive general manager in 2011, Stephanie has held positions of increasing responsibility, including Head of Strategy and Innovation; Chief Transformation Officer; and General Manager of both Commercial and Retail Business Units within the \$3bn electricity utility. Ms. Unwin's experiences range across operational and commercial topics, including managing the retail P&L and an internal team of over 150 people, presiding over multiple complex commercial transactions, including the merger of Verve Energy and Synergy. She also has substantial experience as a company Director with over 15 years of Board engagements across both ASX and TSX including a Non-Executive Director role overseeing the growth of Alacer Gold from a junior ASX listed entity to a \$2bn dual listed company at its height. "I am excited to be leading the Company through this critical stage in its evolution - we now have the commercial and strategic skill sets to complement our discovery team and bring this technology and its application to commercialization".

Dr Robert Hayes is the former Head of Biologics at Amgen and Vice President at Janssen Pharmaceuticals, a Johnson and Johnson company, where he was the Head of Centyrex, a biotechnology company dedicated towards developing novel proteins as therapeutics with transformational properties. During this time, Centyrex entered into a collaboration with Phylogica to understand the ability to use Phylomers to deliver therapeutic proteins into cells.

Dr. Hayes brings over 18 years of experience in biotechnology research and development to Phylogica. In this newly-created role, he will lead all aspects of discovery research at Phylogica. At Amgen, he was responsible for leadership, operational and strategic management of all aspects of biologics preclinical discovery and the biotherapeutics pipeline, including bioreagent generation, large molecule identification, optimization and transition to the manufacturing arm. At Centyrex, Rob established programs resulting in multiple strategic alliances with partners, built a strong proprietary pipeline, and moved multiple product candidates from concept to pre-IND stages in both oncology and immunology. Before that, Dr. Hayes was Director of Antibody Engineering at Xencor, an antibody and protein engineering and development company.

Dr. Hayes received his Ph.D. in Protein Biochemistry from the Imperial College of Science, Technology, and Medicine, and completed his postdoctoral work at UC Berkeley. Earlier in his career, Dr. Hayes held a Royal Society Fellowship and Royal College of Science

Scholarship after receiving his M.Sc degree in Biochemistry from University College, London University.

"My career has been focused on extracellular disease targets because the tools to target intracellular proteins involved in many important diseases have not been available. I am excited at the opportunity to join Phylogica, the industry leader in targeting these intracellular proteins," said Dr. Hayes. "Its innovative drug delivery platform is among the most promising in the biopharmaceutical industry. I look forward to working with Phylogica's world-class research scientists to apply this technology to the discovery of new drug candidates, and to advance their lead candidates into the clinic."

The appointment of the executive management team now secures the commercial and scientific leadership needed for Phylogica to deliver its world leading intracellular delivery technology through pre-clinical development to filing of an Investigational New Drug (IND) application. The executive will be responsible for internationalising the Phylomer platform both scientifically and commercially. In the scientific domain, this will involve assembling additional global experts in the field of intracellular drug delivery to a Scientific Advisory Board and integrating the input of this group with that of the company's outstanding operational team into the drug development plans for the company's delivery technology as well as both existing (iMyc, Stat5 and YB1) and new drug cargoes. On the commercial front, the executive will be responsible for the creation and execution of investment opportunities across R&D collaborations, technology licensing and the Phylomer platform itself with a greater focus on international partners and investors. The executive will further oversee renewal of Phylogica's entire intellectual property portfolio with the commencement of composition of matter claims around its lead delivery and cargo candidates.

Both executives have committed to PYC for a minimum term of 2 years and will seek shareholder endorsement for remuneration packages that closely align executive incentives to shareholder returns. These returns will be driven by progression of the company's lead candidates through key pre-clinical milestones towards clinical evaluation.

"We are delighted by these two appointments who provide the company with both deep commercial and operational capabilities and extensive drug development expertise at a critical time for Phylogica and reflect the increasing promise and maturity of the company's transformational drug delivery technology" says Dr Bernard Hockings, Phylogica board member.

Ms. Unwin adds, "We have many immediate priorities including appointment of a world class, and international scientific advisory board to provide guidance on how to maximize the scientific value of our promising platform, working closely with our own discovery team, and we are looking to build collaborations to partner and maximize the value of our platform". Phylogica has developed multiple delivery-payload combinations based on its proprietary library with a first in class iMyc cargo, against the myc oncogene, a major driver of cancer initiation and progression.

"This is an incredibly exciting area of science with substantially unmet needs in technologies to target major tissues outside of the liver, and approaches to open up the intracellular target space", said Dr Hayes. Phylogica's intracellular delivery approach is potentially a groundbreaking breakthrough and will eventually allow broad targeting of diseases".

For further information, please contact:

Investors	Media
Stephanie Unwin Chair E: stephanieu@phylogica.com M: 0411 132 287	Ben Walsh WE Buchan E: bwalsh@buchanwe.com.au M: 0411 520 012

About Phylogica

Phylogica Limited (ASX: PYC) is an oncology-focused biotech company discovering and developing a new generation of biologics-based therapies against intracellular cancer targets. The company was originally spun out from the Telethon Kids Institute (Perth, Australia) and the Fox Chase Cancer Centre (Philadelphia, USA). Phylogica controls access to the world's most structurally diverse source of peptides - called Phylomers. The company specialises in Phylomer-based solutions to discover and deliver novel biologics drugs against intractable intracellular cancer targets with unprecedented potencies. Within the last six years, the company has entered into discovery collaborations with Roche, Genentech, MedImmune, Pfizer, Janssen and Cubist Pharmaceuticals.